A. Bura-Rivière

2024 ESC Guidelines for the management of peripheral arterial and aortic diseases

Lucia Mazzolai, Gisela Teixidó‐Turà, Stefano Lanzi et al. · European Heart Journal · 2024 · 603 citations · Full text

Pharmacologic Demonstration of the Synergistic Effects of a Combination of the Renin Inhibitor Aliskiren and the AT1 Receptor Antagonist Valsartan on the Angiotensin II–Renin Feedback Interruption

Michel Azizi, Joël Ménard, Alvine Bissery et al. · Journal of the American Society of Nephrology · 2004 · 234 citations

Molecular Pharmacology, Hypertension, Renin Inhibitor Aliskiren +15

Pharmacological properties of S1RA, a new sigma‐1 receptor antagonist that inhibits neuropathic pain and activity‐induced spinal sensitization

Luz Romero, Daniel Zamanillo, Xavier Nadal et al. · British Journal of Pharmacology · 2012 · 179 citations · Full text

The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study.

Bernd Jan Sanson, Paolo Simioni, Daniela Tormene et al. · PubMed · 1999 · 178 citations

Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism

Benjamin Planquette, Laurent Bertoletti, Anaïs Charles‐Nelson et al. · CHEST Journal · 2021 · 142 citations

Thrombosis, Venous Thrombosis, Rivaroxaban Vs Dalteparin +10